Book a Meeting

BetterBet™ Anti-CD38 FcγRIIB Binding Enhanced Antibody (CAT#: AES-0622-ZP412) Datasheet

Target
CD38
Description
Anti-CD38 FcγRIIB Binding Enhanced Antibody achieved by modifying the Fc of the antibody to increase the affinity of the antibody with FcγRIIb.
Applications
Enhancing primate/human antigen eliminating
Technology
FcγRIIB selective binding technology

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced CD38 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
platelet derived growth factor receptor alpha
Background
Platelet Derived Growth Factor Receptor Alpha; Platelet-Derived Growth Factor Receptor; Alpha Polypeptide; Alpha-Type Platelet-Derived Growth Factor Receptor; Platelet-Derived Growth Factor Receptor 2; CD140 Antigen-Like Family Member A; CD140a Antigen; PDGF-R-Alpha; EC 2.7.10.1; PDGFR-2;
Description
Anti-CD38 FcγRIIB Binding Enhanced Antibody achieved by modifying the Fc of the antibody to increase the affinity of the antibody with FcγRIIb.

Due to high homology between inhibitory FcγRIIB and activating FcγRIIA, no successful Fc engineering to selectively enhance FcγRIIB binding has been reported. Since FcγRIIA is expressed on platelet, antibody could crosslink platelets by binding to FcγRIIA expressed on platelet, and has a risk of inducing thrombosis. Therefore, generation of novel Fc variant (FcγRIIB Binding Enhanced Antibody) with selective enhancement of FcγRIIB binding is neccessary. Engineered FcγRIIB Binding Enhanced Antibody could increase efficacy by inducing inhibitory signal into immune cell with strong FcγRIIB binding, in addition to neutralization of immune-activating antigen.

Related Products

ADCC-Enhanced Anti-Human CD38 (MOR202) Antibody (CAT#: BioBet-CB-014LX)
Non-fucosylated Anti-Human CD38 (Daratumumab) Therapeutic Antibody (CAT#: BioBet-017ZP)
BetterBet™ Anti-CD38 Half-Life Extended Antibody (CAT#: AES-0622-ZP1068)
BetterBet™ Anti-CD38 Recycling Antibody (CAT#: AES-0622-ZP84)
Highly Galactosylated Anti-CD38 (Daratumumab) Antibody (CAT#: BioBet-GA-017ZP)
Non-Fucosylated Anti-Human CD38 (38SB) Therapeutic Antibody (CAT#: BioBet-663ZP)
BetterBet™ Anti-CD38 On-Target Antibody (CAT#: AES-0622-ZP740)
ADCC-Enhanced Anti-Human CD38 (Felzartamab) Antibody (CAT#: BioBet-CB-031LX)

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany

ISO 9001 Certified - Creative Biolabs Quality Management System.